Global Biologics and Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2019-2030
Summary
A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.
A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.
According to APO Research, The global Biologics and Biosimilars market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global manufacturers of Biologics and Biosimilars include Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly and Novartis, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Biologics and Biosimilars, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Biologics and Biosimilars, also provides the sales of main regions and countries. Of the upcoming market potential for Biologics and Biosimilars, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Biologics and Biosimilars sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Biologics and Biosimilars market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Biologics and Biosimilars sales, projected growth trends, production technology, application and end-user industry.
Biologics and Biosimilars segment by Company
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics and Biosimilars.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Biologics and Biosimilars market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2019-2030).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biologics and Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Biologics and Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Biologics and Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.
A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.
According to APO Research, The global Biologics and Biosimilars market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global manufacturers of Biologics and Biosimilars include Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly and Novartis, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Biologics and Biosimilars, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Biologics and Biosimilars, also provides the sales of main regions and countries. Of the upcoming market potential for Biologics and Biosimilars, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Biologics and Biosimilars sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Biologics and Biosimilars market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Biologics and Biosimilars sales, projected growth trends, production technology, application and end-user industry.
Biologics and Biosimilars segment by Company
- Roche
- Amgen
- AbbVie
- Sanofi-Aventis
- Johnson & Johnson
- Pfizer
- Novo Nordisk
- Eli Lilly
- Novartis
- Merck
- 3sbio
- Changchun High Tech
- CP Guojian
- Biotech
- Gelgen
- Innovent
- Dong Bao
- Ganlee
- United Laboratories
- Monoclonal Antibodies
- Interferon
- Erythropoietin
- Insulin
- Vaccines
- Others
- Tumor
- Diabetes
- Cardiovascular
- Hemophilia
- Others
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics and Biosimilars.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Biologics and Biosimilars market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2019-2030).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biologics and Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Biologics and Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Biologics and Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
1 MARKET OVERVIEW
1.1 Product Definition
1.2 Global Biologics and Biosimilars Market Size, 2019 VS 2023 VS 2030
1.3 Global Biologics and Biosimilars Market Size Estimates and Forecasts (2019-2030)
1.4 Global Biologics and Biosimilars Sales Estimates and Forecasts (2019-2030)
1.5 Global Biologics and Biosimilars Market Average Price (2019-2030)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 GLOBAL BIOLOGICS AND BIOSIMILARS MARKET DYNAMICS
2.1 Biologics and Biosimilars Industry Trends
2.2 Biologics and Biosimilars Industry Drivers
2.3 Biologics and Biosimilars Industry Opportunities and Challenges
2.4 Biologics and Biosimilars Industry Restraints
3 BIOLOGICS AND BIOSIMILARS MARKET BY MANUFACTURERS
3.1 Global Biologics and Biosimilars Revenue by Manufacturers (2019-2024)
3.2 Global Biologics and Biosimilars Sales by Manufacturers (2019-2024)
3.3 Global Biologics and Biosimilars Average Sales Price by Manufacturers (2019-2024)
3.4 Global Biologics and Biosimilars Industry Manufacturers Ranking, 2022 VS 2023 VS 2024
3.5 Global Biologics and Biosimilars Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Biologics and Biosimilars Manufacturers, Product Type & Application
3.7 Global Biologics and Biosimilars Manufacturers Commercialization Time
3.8 Market Competitive Analysis
3.8.1 Global Biologics and Biosimilars Market CR5 and HHI
3.8.2 Global Top 5 and 10 Biologics and Biosimilars Players Market Share by Revenue in 2023
3.8.3 2023 Biologics and Biosimilars Tier 1, Tier 2, and Tier
4 BIOLOGICS AND BIOSIMILARS MARKET BY TYPE
4.1 Biologics and Biosimilars Type Introduction
4.1.1 Monoclonal Antibodies
4.1.2 Interferon
4.1.3 Erythropoietin
4.1.4 Insulin
4.1.5 Vaccines
4.1.6 Others
4.2 Global Biologics and Biosimilars Sales by Type
4.2.1 Global Biologics and Biosimilars Sales by Type (2019 VS 2023 VS 2030)
4.2.2 Global Biologics and Biosimilars Sales by Type (2019-2030)
4.2.3 Global Biologics and Biosimilars Sales Market Share by Type (2019-2030)
4.3 Global Biologics and Biosimilars Revenue by Type
4.3.1 Global Biologics and Biosimilars Revenue by Type (2019 VS 2023 VS 2030)
4.3.2 Global Biologics and Biosimilars Revenue by Type (2019-2030)
4.3.3 Global Biologics and Biosimilars Revenue Market Share by Type (2019-2030)
5 BIOLOGICS AND BIOSIMILARS MARKET BY APPLICATION
5.1 Biologics and Biosimilars Application Introduction
5.1.1 Tumor
5.1.2 Diabetes
5.1.3 Cardiovascular
5.1.4 Hemophilia
5.1.5 Others
5.2 Global Biologics and Biosimilars Sales by Application
5.2.1 Global Biologics and Biosimilars Sales by Application (2019 VS 2023 VS 2030)
5.2.2 Global Biologics and Biosimilars Sales by Application (2019-2030)
5.2.3 Global Biologics and Biosimilars Sales Market Share by Application (2019-2030)
5.3 Global Biologics and Biosimilars Revenue by Application
5.3.1 Global Biologics and Biosimilars Revenue by Application (2019 VS 2023 VS 2030)
5.3.2 Global Biologics and Biosimilars Revenue by Application (2019-2030)
5.3.3 Global Biologics and Biosimilars Revenue Market Share by Application (2019-2030)
6 GLOBAL BIOLOGICS AND BIOSIMILARS SALES BY REGION
6.1 Global Biologics and Biosimilars Sales by Region: 2019 VS 2023 VS 2030
6.2 Global Biologics and Biosimilars Sales by Region (2019-2030)
6.2.1 Global Biologics and Biosimilars Sales by Region (2019-2024)
6.2.2 Global Biologics and Biosimilars Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Biologics and Biosimilars Sales Growth Rate by Country: 2019 VS 2023 VS 2030
6.3.2 North America Biologics and Biosimilars Sales by Country (2019-2030)
6.3.3 U.S.
6.3.4 Canada
6.4 Europe
6.4.1 Europe Biologics and Biosimilars Sales Growth Rate by Country: 2019 VS 2023 VS 2030
6.4.2 Europe Biologics and Biosimilars Sales by Country (2019-2030)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Biologics and Biosimilars Sales Growth Rate by Country: 2019 VS 2023 VS 2030
6.5.2 Asia Pacific Biologics and Biosimilars Sales by Country (2019-2030)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 LAMEA
6.6.1 LAMEA Biologics and Biosimilars Sales Growth Rate by Country: 2019 VS 2023 VS 2030
6.6.2 LAMEA Biologics and Biosimilars Sales by Country (2019-2030)
6.6.3 Mexico
6.6.4 Brazil
6.6.5 Turkey
6.6.6 GCC Countries
7 GLOBAL BIOLOGICS AND BIOSIMILARS REVENUE BY REGION
7.1 Global Biologics and Biosimilars Revenue by Region
7.1.1 Global Biologics and Biosimilars Revenue by Region: 2019 VS 2023 VS 2030
7.1.2 Global Biologics and Biosimilars Revenue by Region (2019-2024)
7.1.3 Global Biologics and Biosimilars Revenue by Region (2025-2030)
7.1.4 Global Biologics and Biosimilars Revenue Market Share by Region (2019-2030)
7.2 North America
7.2.1 North America Biologics and Biosimilars Revenue (2019-2030)
7.2.2 North America Biologics and Biosimilars Revenue Share by Country: 2019 VS 2023 VS 2030
7.3 Europe
7.3.1 Europe Biologics and Biosimilars Revenue (2019-2030)
7.3.2 Europe Biologics and Biosimilars Revenue Share by Country: 2019 VS 2023 VS 2030
7.4 Asia-Pacific
7.4.1 Asia-Pacific Biologics and Biosimilars Revenue (2019-2030)
7.4.2 Asia-Pacific Biologics and Biosimilars Revenue Share by Country: 2019 VS 2023 VS 2030
7.5 LAMEA
7.5.1 LAMEA Biologics and Biosimilars Revenue (2019-2030)
7.5.2 LAMEA Biologics and Biosimilars Revenue Share by Country: 2019 VS 2023 VS 2030
8 COMPANY PROFILES
8.1 Roche
8.1.1 Roche Comapny Information
8.1.2 Roche Business Overview
8.1.3 Roche Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.1.4 Roche Biologics and Biosimilars Product Portfolio
8.1.5 Roche Recent Developments
8.2 Amgen
8.2.1 Amgen Comapny Information
8.2.2 Amgen Business Overview
8.2.3 Amgen Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.2.4 Amgen Biologics and Biosimilars Product Portfolio
8.2.5 Amgen Recent Developments
8.3 AbbVie
8.3.1 AbbVie Comapny Information
8.3.2 AbbVie Business Overview
8.3.3 AbbVie Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.3.4 AbbVie Biologics and Biosimilars Product Portfolio
8.3.5 AbbVie Recent Developments
8.4 Sanofi-Aventis
8.4.1 Sanofi-Aventis Comapny Information
8.4.2 Sanofi-Aventis Business Overview
8.4.3 Sanofi-Aventis Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.4.4 Sanofi-Aventis Biologics and Biosimilars Product Portfolio
8.4.5 Sanofi-Aventis Recent Developments
8.5 Johnson & Johnson
8.5.1 Johnson & Johnson Comapny Information
8.5.2 Johnson & Johnson Business Overview
8.5.3 Johnson & Johnson Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.5.4 Johnson & Johnson Biologics and Biosimilars Product Portfolio
8.5.5 Johnson & Johnson Recent Developments
8.6 Pfizer
8.6.1 Pfizer Comapny Information
8.6.2 Pfizer Business Overview
8.6.3 Pfizer Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.6.4 Pfizer Biologics and Biosimilars Product Portfolio
8.6.5 Pfizer Recent Developments
8.7 Novo Nordisk
8.7.1 Novo Nordisk Comapny Information
8.7.2 Novo Nordisk Business Overview
8.7.3 Novo Nordisk Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.7.4 Novo Nordisk Biologics and Biosimilars Product Portfolio
8.7.5 Novo Nordisk Recent Developments
8.8 Eli Lilly
8.8.1 Eli Lilly Comapny Information
8.8.2 Eli Lilly Business Overview
8.8.3 Eli Lilly Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.8.4 Eli Lilly Biologics and Biosimilars Product Portfolio
8.8.5 Eli Lilly Recent Developments
8.9 Novartis
8.9.1 Novartis Comapny Information
8.9.2 Novartis Business Overview
8.9.3 Novartis Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.9.4 Novartis Biologics and Biosimilars Product Portfolio
8.9.5 Novartis Recent Developments
8.10 Merck
8.10.1 Merck Comapny Information
8.10.2 Merck Business Overview
8.10.3 Merck Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.10.4 Merck Biologics and Biosimilars Product Portfolio
8.10.5 Merck Recent Developments
8.11 3sbio
8.11.1 3sbio Comapny Information
8.11.2 3sbio Business Overview
8.11.3 3sbio Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.11.4 3sbio Biologics and Biosimilars Product Portfolio
8.11.5 3sbio Recent Developments
8.12 Changchun High Tech
8.12.1 Changchun High Tech Comapny Information
8.12.2 Changchun High Tech Business Overview
8.12.3 Changchun High Tech Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.12.4 Changchun High Tech Biologics and Biosimilars Product Portfolio
8.12.5 Changchun High Tech Recent Developments
8.13 CP Guojian
8.13.1 CP Guojian Comapny Information
8.13.2 CP Guojian Business Overview
8.13.3 CP Guojian Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.13.4 CP Guojian Biologics and Biosimilars Product Portfolio
8.13.5 CP Guojian Recent Developments
8.14 Biotech
8.14.1 Biotech Comapny Information
8.14.2 Biotech Business Overview
8.14.3 Biotech Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.14.4 Biotech Biologics and Biosimilars Product Portfolio
8.14.5 Biotech Recent Developments
8.15 Gelgen
8.15.1 Gelgen Comapny Information
8.15.2 Gelgen Business Overview
8.15.3 Gelgen Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.15.4 Gelgen Biologics and Biosimilars Product Portfolio
8.15.5 Gelgen Recent Developments
8.16 Innovent
8.16.1 Innovent Comapny Information
8.16.2 Innovent Business Overview
8.16.3 Innovent Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.16.4 Innovent Biologics and Biosimilars Product Portfolio
8.16.5 Innovent Recent Developments
8.17 Dong Bao
8.17.1 Dong Bao Comapny Information
8.17.2 Dong Bao Business Overview
8.17.3 Dong Bao Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.17.4 Dong Bao Biologics and Biosimilars Product Portfolio
8.17.5 Dong Bao Recent Developments
8.18 Ganlee
8.18.1 Ganlee Comapny Information
8.18.2 Ganlee Business Overview
8.18.3 Ganlee Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.18.4 Ganlee Biologics and Biosimilars Product Portfolio
8.18.5 Ganlee Recent Developments
8.19 United Laboratories
8.19.1 United Laboratories Comapny Information
8.19.2 United Laboratories Business Overview
8.19.3 United Laboratories Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.19.4 United Laboratories Biologics and Biosimilars Product Portfolio
8.19.5 United Laboratories Recent Developments
9 VALUE CHAIN AND SALES CHANNELS ANALYSIS
9.1 Biologics and Biosimilars Value Chain Analysis
9.1.1 Biologics and Biosimilars Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Biologics and Biosimilars Production Mode & Process
9.2 Biologics and Biosimilars Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Biologics and Biosimilars Distributors
9.2.3 Biologics and Biosimilars Customers
10 CONCLUDING INSIGHTS
11 APPENDIX
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
1.1 Product Definition
1.2 Global Biologics and Biosimilars Market Size, 2019 VS 2023 VS 2030
1.3 Global Biologics and Biosimilars Market Size Estimates and Forecasts (2019-2030)
1.4 Global Biologics and Biosimilars Sales Estimates and Forecasts (2019-2030)
1.5 Global Biologics and Biosimilars Market Average Price (2019-2030)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 GLOBAL BIOLOGICS AND BIOSIMILARS MARKET DYNAMICS
2.1 Biologics and Biosimilars Industry Trends
2.2 Biologics and Biosimilars Industry Drivers
2.3 Biologics and Biosimilars Industry Opportunities and Challenges
2.4 Biologics and Biosimilars Industry Restraints
3 BIOLOGICS AND BIOSIMILARS MARKET BY MANUFACTURERS
3.1 Global Biologics and Biosimilars Revenue by Manufacturers (2019-2024)
3.2 Global Biologics and Biosimilars Sales by Manufacturers (2019-2024)
3.3 Global Biologics and Biosimilars Average Sales Price by Manufacturers (2019-2024)
3.4 Global Biologics and Biosimilars Industry Manufacturers Ranking, 2022 VS 2023 VS 2024
3.5 Global Biologics and Biosimilars Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Biologics and Biosimilars Manufacturers, Product Type & Application
3.7 Global Biologics and Biosimilars Manufacturers Commercialization Time
3.8 Market Competitive Analysis
3.8.1 Global Biologics and Biosimilars Market CR5 and HHI
3.8.2 Global Top 5 and 10 Biologics and Biosimilars Players Market Share by Revenue in 2023
3.8.3 2023 Biologics and Biosimilars Tier 1, Tier 2, and Tier
4 BIOLOGICS AND BIOSIMILARS MARKET BY TYPE
4.1 Biologics and Biosimilars Type Introduction
4.1.1 Monoclonal Antibodies
4.1.2 Interferon
4.1.3 Erythropoietin
4.1.4 Insulin
4.1.5 Vaccines
4.1.6 Others
4.2 Global Biologics and Biosimilars Sales by Type
4.2.1 Global Biologics and Biosimilars Sales by Type (2019 VS 2023 VS 2030)
4.2.2 Global Biologics and Biosimilars Sales by Type (2019-2030)
4.2.3 Global Biologics and Biosimilars Sales Market Share by Type (2019-2030)
4.3 Global Biologics and Biosimilars Revenue by Type
4.3.1 Global Biologics and Biosimilars Revenue by Type (2019 VS 2023 VS 2030)
4.3.2 Global Biologics and Biosimilars Revenue by Type (2019-2030)
4.3.3 Global Biologics and Biosimilars Revenue Market Share by Type (2019-2030)
5 BIOLOGICS AND BIOSIMILARS MARKET BY APPLICATION
5.1 Biologics and Biosimilars Application Introduction
5.1.1 Tumor
5.1.2 Diabetes
5.1.3 Cardiovascular
5.1.4 Hemophilia
5.1.5 Others
5.2 Global Biologics and Biosimilars Sales by Application
5.2.1 Global Biologics and Biosimilars Sales by Application (2019 VS 2023 VS 2030)
5.2.2 Global Biologics and Biosimilars Sales by Application (2019-2030)
5.2.3 Global Biologics and Biosimilars Sales Market Share by Application (2019-2030)
5.3 Global Biologics and Biosimilars Revenue by Application
5.3.1 Global Biologics and Biosimilars Revenue by Application (2019 VS 2023 VS 2030)
5.3.2 Global Biologics and Biosimilars Revenue by Application (2019-2030)
5.3.3 Global Biologics and Biosimilars Revenue Market Share by Application (2019-2030)
6 GLOBAL BIOLOGICS AND BIOSIMILARS SALES BY REGION
6.1 Global Biologics and Biosimilars Sales by Region: 2019 VS 2023 VS 2030
6.2 Global Biologics and Biosimilars Sales by Region (2019-2030)
6.2.1 Global Biologics and Biosimilars Sales by Region (2019-2024)
6.2.2 Global Biologics and Biosimilars Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Biologics and Biosimilars Sales Growth Rate by Country: 2019 VS 2023 VS 2030
6.3.2 North America Biologics and Biosimilars Sales by Country (2019-2030)
6.3.3 U.S.
6.3.4 Canada
6.4 Europe
6.4.1 Europe Biologics and Biosimilars Sales Growth Rate by Country: 2019 VS 2023 VS 2030
6.4.2 Europe Biologics and Biosimilars Sales by Country (2019-2030)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Biologics and Biosimilars Sales Growth Rate by Country: 2019 VS 2023 VS 2030
6.5.2 Asia Pacific Biologics and Biosimilars Sales by Country (2019-2030)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 LAMEA
6.6.1 LAMEA Biologics and Biosimilars Sales Growth Rate by Country: 2019 VS 2023 VS 2030
6.6.2 LAMEA Biologics and Biosimilars Sales by Country (2019-2030)
6.6.3 Mexico
6.6.4 Brazil
6.6.5 Turkey
6.6.6 GCC Countries
7 GLOBAL BIOLOGICS AND BIOSIMILARS REVENUE BY REGION
7.1 Global Biologics and Biosimilars Revenue by Region
7.1.1 Global Biologics and Biosimilars Revenue by Region: 2019 VS 2023 VS 2030
7.1.2 Global Biologics and Biosimilars Revenue by Region (2019-2024)
7.1.3 Global Biologics and Biosimilars Revenue by Region (2025-2030)
7.1.4 Global Biologics and Biosimilars Revenue Market Share by Region (2019-2030)
7.2 North America
7.2.1 North America Biologics and Biosimilars Revenue (2019-2030)
7.2.2 North America Biologics and Biosimilars Revenue Share by Country: 2019 VS 2023 VS 2030
7.3 Europe
7.3.1 Europe Biologics and Biosimilars Revenue (2019-2030)
7.3.2 Europe Biologics and Biosimilars Revenue Share by Country: 2019 VS 2023 VS 2030
7.4 Asia-Pacific
7.4.1 Asia-Pacific Biologics and Biosimilars Revenue (2019-2030)
7.4.2 Asia-Pacific Biologics and Biosimilars Revenue Share by Country: 2019 VS 2023 VS 2030
7.5 LAMEA
7.5.1 LAMEA Biologics and Biosimilars Revenue (2019-2030)
7.5.2 LAMEA Biologics and Biosimilars Revenue Share by Country: 2019 VS 2023 VS 2030
8 COMPANY PROFILES
8.1 Roche
8.1.1 Roche Comapny Information
8.1.2 Roche Business Overview
8.1.3 Roche Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.1.4 Roche Biologics and Biosimilars Product Portfolio
8.1.5 Roche Recent Developments
8.2 Amgen
8.2.1 Amgen Comapny Information
8.2.2 Amgen Business Overview
8.2.3 Amgen Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.2.4 Amgen Biologics and Biosimilars Product Portfolio
8.2.5 Amgen Recent Developments
8.3 AbbVie
8.3.1 AbbVie Comapny Information
8.3.2 AbbVie Business Overview
8.3.3 AbbVie Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.3.4 AbbVie Biologics and Biosimilars Product Portfolio
8.3.5 AbbVie Recent Developments
8.4 Sanofi-Aventis
8.4.1 Sanofi-Aventis Comapny Information
8.4.2 Sanofi-Aventis Business Overview
8.4.3 Sanofi-Aventis Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.4.4 Sanofi-Aventis Biologics and Biosimilars Product Portfolio
8.4.5 Sanofi-Aventis Recent Developments
8.5 Johnson & Johnson
8.5.1 Johnson & Johnson Comapny Information
8.5.2 Johnson & Johnson Business Overview
8.5.3 Johnson & Johnson Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.5.4 Johnson & Johnson Biologics and Biosimilars Product Portfolio
8.5.5 Johnson & Johnson Recent Developments
8.6 Pfizer
8.6.1 Pfizer Comapny Information
8.6.2 Pfizer Business Overview
8.6.3 Pfizer Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.6.4 Pfizer Biologics and Biosimilars Product Portfolio
8.6.5 Pfizer Recent Developments
8.7 Novo Nordisk
8.7.1 Novo Nordisk Comapny Information
8.7.2 Novo Nordisk Business Overview
8.7.3 Novo Nordisk Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.7.4 Novo Nordisk Biologics and Biosimilars Product Portfolio
8.7.5 Novo Nordisk Recent Developments
8.8 Eli Lilly
8.8.1 Eli Lilly Comapny Information
8.8.2 Eli Lilly Business Overview
8.8.3 Eli Lilly Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.8.4 Eli Lilly Biologics and Biosimilars Product Portfolio
8.8.5 Eli Lilly Recent Developments
8.9 Novartis
8.9.1 Novartis Comapny Information
8.9.2 Novartis Business Overview
8.9.3 Novartis Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.9.4 Novartis Biologics and Biosimilars Product Portfolio
8.9.5 Novartis Recent Developments
8.10 Merck
8.10.1 Merck Comapny Information
8.10.2 Merck Business Overview
8.10.3 Merck Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.10.4 Merck Biologics and Biosimilars Product Portfolio
8.10.5 Merck Recent Developments
8.11 3sbio
8.11.1 3sbio Comapny Information
8.11.2 3sbio Business Overview
8.11.3 3sbio Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.11.4 3sbio Biologics and Biosimilars Product Portfolio
8.11.5 3sbio Recent Developments
8.12 Changchun High Tech
8.12.1 Changchun High Tech Comapny Information
8.12.2 Changchun High Tech Business Overview
8.12.3 Changchun High Tech Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.12.4 Changchun High Tech Biologics and Biosimilars Product Portfolio
8.12.5 Changchun High Tech Recent Developments
8.13 CP Guojian
8.13.1 CP Guojian Comapny Information
8.13.2 CP Guojian Business Overview
8.13.3 CP Guojian Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.13.4 CP Guojian Biologics and Biosimilars Product Portfolio
8.13.5 CP Guojian Recent Developments
8.14 Biotech
8.14.1 Biotech Comapny Information
8.14.2 Biotech Business Overview
8.14.3 Biotech Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.14.4 Biotech Biologics and Biosimilars Product Portfolio
8.14.5 Biotech Recent Developments
8.15 Gelgen
8.15.1 Gelgen Comapny Information
8.15.2 Gelgen Business Overview
8.15.3 Gelgen Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.15.4 Gelgen Biologics and Biosimilars Product Portfolio
8.15.5 Gelgen Recent Developments
8.16 Innovent
8.16.1 Innovent Comapny Information
8.16.2 Innovent Business Overview
8.16.3 Innovent Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.16.4 Innovent Biologics and Biosimilars Product Portfolio
8.16.5 Innovent Recent Developments
8.17 Dong Bao
8.17.1 Dong Bao Comapny Information
8.17.2 Dong Bao Business Overview
8.17.3 Dong Bao Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.17.4 Dong Bao Biologics and Biosimilars Product Portfolio
8.17.5 Dong Bao Recent Developments
8.18 Ganlee
8.18.1 Ganlee Comapny Information
8.18.2 Ganlee Business Overview
8.18.3 Ganlee Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.18.4 Ganlee Biologics and Biosimilars Product Portfolio
8.18.5 Ganlee Recent Developments
8.19 United Laboratories
8.19.1 United Laboratories Comapny Information
8.19.2 United Laboratories Business Overview
8.19.3 United Laboratories Biologics and Biosimilars Sales, Price, Revenue and Gross Margin (2019-2024)
8.19.4 United Laboratories Biologics and Biosimilars Product Portfolio
8.19.5 United Laboratories Recent Developments
9 VALUE CHAIN AND SALES CHANNELS ANALYSIS
9.1 Biologics and Biosimilars Value Chain Analysis
9.1.1 Biologics and Biosimilars Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Biologics and Biosimilars Production Mode & Process
9.2 Biologics and Biosimilars Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Biologics and Biosimilars Distributors
9.2.3 Biologics and Biosimilars Customers
10 CONCLUDING INSIGHTS
11 APPENDIX
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
LIST OF TABLES
Table 1. Biologics and Biosimilars Industry Trends
Table 2. Biologics and Biosimilars Industry Drivers
Table 3. Biologics and Biosimilars Industry Opportunities and Challenges
Table 4. Biologics and Biosimilars Industry Restraints
Table 5. Global Biologics and Biosimilars Revenue by Manufacturers (US$ Million) & (2019-2024)
Table 6. Global Biologics and Biosimilars Revenue Market Share by Manufacturers (2019-2024)
Table 7. Global Biologics and Biosimilars Sales by Manufacturers (K Units) & (2019-2024)
Table 8. Global Biologics and Biosimilars Sales Market Share by Manufacturers
Table 9. Global Biologics and Biosimilars Average Sales Price (USD/Unit) of Manufacturers (2019-2024)
Table 10. Global Biologics and Biosimilars Industry Manufacturers Ranking, 2022 VS 2023 VS 2024
Table 11. Global Biologics and Biosimilars Key Manufacturers Manufacturing Sites & Headquarters
Table 12. Global Biologics and Biosimilars Manufacturers, Product Type & Application
Table 13. Global Biologics and Biosimilars Manufacturers Commercialization Time
Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Global Biologics and Biosimilars by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 16. Major Manufacturers of Monoclonal Antibodies
Table 17. Major Manufacturers of Interferon
Table 18. Major Manufacturers of Erythropoietin
Table 19. Major Manufacturers of Insulin
Table 20. Major Manufacturers of Vaccines
Table 21. Major Manufacturers of Others
Table 22. Global Biologics and Biosimilars Sales by Type 2019 VS 2023 VS 2030 (K Units)
Table 23. Global Biologics and Biosimilars Sales by Type (2019-2024) & (K Units)
Table 24. Global Biologics and Biosimilars Sales by Type (2025-2030) & (K Units)
Table 25. Global Biologics and Biosimilars Sales Market Share by Type (2019-2024)
Table 26. Global Biologics and Biosimilars Sales Market Share by Type (2025-2030)
Table 27. Global Biologics and Biosimilars Revenue by Type 2019 VS 2023 VS 2030 (K Units)
Table 28. Global Biologics and Biosimilars Revenue by Type (2019-2024) & (K Units)
Table 29. Global Biologics and Biosimilars Revenue by Type (2025-2030) & (K Units)
Table 30. Global Biologics and Biosimilars Revenue Market Share by Type (2019-2024)
Table 31. Global Biologics and Biosimilars Revenue Market Share by Type (2025-2030)
Table 32. Major Manufacturers of Tumor
Table 33. Major Manufacturers of Diabetes
Table 34. Major Manufacturers of Cardiovascular
Table 35. Major Manufacturers of Hemophilia
Table 36. Major Manufacturers of Others
Table 37. Global Biologics and Biosimilars Sales by Application 2019 VS 2023 VS 2030 (K Units)
Table 38. Global Biologics and Biosimilars Sales by Application (2019-2024) & (K Units)
Table 39. Global Biologics and Biosimilars Sales by Application (2025-2030) & (K Units)
Table 40. Global Biologics and Biosimilars Sales Market Share by Application (2019-2024)
Table 41. Global Biologics and Biosimilars Sales Market Share by Application (2025-2030)
Table 42. Global Biologics and Biosimilars Revenue by Application 2019 VS 2023 VS 2030 (K Units)
Table 43. Global Biologics and Biosimilars Revenue by Application (2019-2024) & (K Units)
Table 44. Global Biologics and Biosimilars Revenue by Application (2025-2030) & (K Units)
Table 45. Global Biologics and Biosimilars Revenue Market Share by Application (2019-2024)
Table 46. Global Biologics and Biosimilars Revenue Market Share by Application (2025-2030)
Table 47. Global Biologics and Biosimilars Sales by Region: 2019 VS 2023 VS 2030 (K Units)
Table 48. Global Biologics and Biosimilars Sales by Region (2019-2024) & (K Units)
Table 49. Global Biologics and Biosimilars Sales Market Share by Region (2019-2024)
Table 50. Global Biologics and Biosimilars Sales Forecasted by Region (2025-2030) & (K Units)
Table 51. Global Biologics and Biosimilars Sales Forecasted Market Share by Region (2025-2030)
Table 52. North America Biologics and Biosimilars Sales Growth Rate by Country: 2019 VS 2023 VS 2030 (K Units)
Table 53. North America Biologics and Biosimilars Sales by Country (2019-2024) & (K Units)
Table 54. North America Biologics and Biosimilars Sales by Country (2025-2030) & (K Units)
Table 55. Europe Biologics and Biosimilars Sales Growth Rate by Country: 2019 VS 2023 VS 2030 (K Units)
Table 56. Europe Biologics and Biosimilars Sales by Country (2019-2024) & (K Units)
Table 57. Europe Biologics and Biosimilars Sales by Country (2025-2030) & (K Units)
Table 58. Asia Pacific Biologics and Biosimilars Sales Growth Rate by Country: 2019 VS 2023 VS 2030 (K Units)
Table 59. Asia Pacific Biologics and Biosimilars Sales by Country (2019-2024) & (K Units)
Table 60. Asia Pacific Biologics and Biosimilars Sales by Country (2025-2030) & (K Units)
Table 61. LAMEA Biologics and Biosimilars Sales Growth Rate by Country: 2019 VS 2023 VS 2030 (K Units)
Table 62. LAMEA Biologics and Biosimilars Sales by Country (2019-2024) & (K Units)
Table 63. LAMEA Biologics and Biosimilars Sales by Country (2025-2030) & (K Units)
Table 64. Global Biologics and Biosimilars Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 65. Global Biologics and Biosimilars Revenue by Region (2019-2024) & (US$ Million)
Table 66. Global Biologics and Biosimilars Revenue by Region (2025-2030) & (US$ Million)
Table 67. Global Biologics and Biosimilars Revenue Market Share by Region (2019-2024)
Table 68. Global Biologics and Biosimilars Revenue Market Share by Region (2025-2030)
Table 69. Roche Company Information
Table 70. Roche Business Overview
Table 71. Roche Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 72. Roche Biologics and Biosimilars Product Portfolio
Table 73. Roche Recent Development
Table 74. Amgen Company Information
Table 75. Amgen Business Overview
Table 76. Amgen Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 77. Amgen Biologics and Biosimilars Product Portfolio
Table 78. Amgen Recent Development
Table 79. AbbVie Company Information
Table 80. AbbVie Business Overview
Table 81. AbbVie Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 82. AbbVie Biologics and Biosimilars Product Portfolio
Table 83. AbbVie Recent Development
Table 84. Sanofi-Aventis Company Information
Table 85. Sanofi-Aventis Business Overview
Table 86. Sanofi-Aventis Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 87. Sanofi-Aventis Biologics and Biosimilars Product Portfolio
Table 88. Sanofi-Aventis Recent Development
Table 89. Johnson & Johnson Company Information
Table 90. Johnson & Johnson Business Overview
Table 91. Johnson & Johnson Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 92. Johnson & Johnson Biologics and Biosimilars Product Portfolio
Table 93. Johnson & Johnson Recent Development
Table 94. Pfizer Company Information
Table 95. Pfizer Business Overview
Table 96. Pfizer Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 97. Pfizer Biologics and Biosimilars Product Portfolio
Table 98. Pfizer Recent Development
Table 99. Novo Nordisk Company Information
Table 100. Novo Nordisk Business Overview
Table 101. Novo Nordisk Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 102. Novo Nordisk Biologics and Biosimilars Product Portfolio
Table 103. Novo Nordisk Recent Development
Table 104. Eli Lilly Company Information
Table 105. Eli Lilly Business Overview
Table 106. Eli Lilly Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 107. Eli Lilly Biologics and Biosimilars Product Portfolio
Table 108. Eli Lilly Recent Development
Table 109. Novartis Company Information
Table 110. Novartis Business Overview
Table 111. Novartis Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 112. Novartis Biologics and Biosimilars Product Portfolio
Table 113. Novartis Recent Development
Table 114. Merck Company Information
Table 115. Merck Business Overview
Table 116. Merck Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 117. Merck Biologics and Biosimilars Product Portfolio
Table 118. Merck Recent Development
Table 119. 3sbio Company Information
Table 120. 3sbio Business Overview
Table 121. 3sbio Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 122. 3sbio Biologics and Biosimilars Product Portfolio
Table 123. 3sbio Recent Development
Table 124. Changchun High Tech Company Information
Table 125. Changchun High Tech Business Overview
Table 126. Changchun High Tech Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 127. Changchun High Tech Biologics and Biosimilars Product Portfolio
Table 128. Changchun High Tech Recent Development
Table 129. CP Guojian Company Information
Table 130. CP Guojian Business Overview
Table 131. CP Guojian Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 132. CP Guojian Biologics and Biosimilars Product Portfolio
Table 133. CP Guojian Recent Development
Table 134. Biotech Company Information
Table 135. Biotech Business Overview
Table 136. Biotech Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 137. Biotech Biologics and Biosimilars Product Portfolio
Table 138. Biotech Recent Development
Table 139. Gelgen Company Information
Table 140. Gelgen Business Overview
Table 141. Gelgen Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 142. Gelgen Biologics and Biosimilars Product Portfolio
Table 143. Gelgen Recent Development
Table 144. Innovent Company Information
Table 145. Innovent Business Overview
Table 146. Innovent Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 147. Innovent Biologics and Biosimilars Product Portfolio
Table 148. Innovent Recent Development
Table 149. Dong Bao Company Information
Table 150. Dong Bao Business Overview
Table 151. Dong Bao Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 152. Dong Bao Biologics and Biosimilars Product Portfolio
Table 153. Dong Bao Recent Development
Table 154. Ganlee Company Information
Table 155. Ganlee Business Overview
Table 156. Ganlee Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 157. Ganlee Biologics and Biosimilars Product Portfolio
Table 158. Ganlee Recent Development
Table 159. United Laboratories Company Information
Table 160. United Laboratories Business Overview
Table 161. United Laboratories Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 162. United Laboratories Biologics and Biosimilars Product Portfolio
Table 163. United Laboratories Recent Development
Table 164. Key Raw Materials
Table 165. Raw Materials Key Suppliers
Table 166. Biologics and Biosimilars Distributors List
Table 167. Biologics and Biosimilars Customers List
Table 168. Research Programs/Design for This Report
Table 169. Authors List of This Report
Table 170. Secondary Sources
Table 171. Primary Sources
Table 1. Biologics and Biosimilars Industry Trends
Table 2. Biologics and Biosimilars Industry Drivers
Table 3. Biologics and Biosimilars Industry Opportunities and Challenges
Table 4. Biologics and Biosimilars Industry Restraints
Table 5. Global Biologics and Biosimilars Revenue by Manufacturers (US$ Million) & (2019-2024)
Table 6. Global Biologics and Biosimilars Revenue Market Share by Manufacturers (2019-2024)
Table 7. Global Biologics and Biosimilars Sales by Manufacturers (K Units) & (2019-2024)
Table 8. Global Biologics and Biosimilars Sales Market Share by Manufacturers
Table 9. Global Biologics and Biosimilars Average Sales Price (USD/Unit) of Manufacturers (2019-2024)
Table 10. Global Biologics and Biosimilars Industry Manufacturers Ranking, 2022 VS 2023 VS 2024
Table 11. Global Biologics and Biosimilars Key Manufacturers Manufacturing Sites & Headquarters
Table 12. Global Biologics and Biosimilars Manufacturers, Product Type & Application
Table 13. Global Biologics and Biosimilars Manufacturers Commercialization Time
Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Global Biologics and Biosimilars by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 16. Major Manufacturers of Monoclonal Antibodies
Table 17. Major Manufacturers of Interferon
Table 18. Major Manufacturers of Erythropoietin
Table 19. Major Manufacturers of Insulin
Table 20. Major Manufacturers of Vaccines
Table 21. Major Manufacturers of Others
Table 22. Global Biologics and Biosimilars Sales by Type 2019 VS 2023 VS 2030 (K Units)
Table 23. Global Biologics and Biosimilars Sales by Type (2019-2024) & (K Units)
Table 24. Global Biologics and Biosimilars Sales by Type (2025-2030) & (K Units)
Table 25. Global Biologics and Biosimilars Sales Market Share by Type (2019-2024)
Table 26. Global Biologics and Biosimilars Sales Market Share by Type (2025-2030)
Table 27. Global Biologics and Biosimilars Revenue by Type 2019 VS 2023 VS 2030 (K Units)
Table 28. Global Biologics and Biosimilars Revenue by Type (2019-2024) & (K Units)
Table 29. Global Biologics and Biosimilars Revenue by Type (2025-2030) & (K Units)
Table 30. Global Biologics and Biosimilars Revenue Market Share by Type (2019-2024)
Table 31. Global Biologics and Biosimilars Revenue Market Share by Type (2025-2030)
Table 32. Major Manufacturers of Tumor
Table 33. Major Manufacturers of Diabetes
Table 34. Major Manufacturers of Cardiovascular
Table 35. Major Manufacturers of Hemophilia
Table 36. Major Manufacturers of Others
Table 37. Global Biologics and Biosimilars Sales by Application 2019 VS 2023 VS 2030 (K Units)
Table 38. Global Biologics and Biosimilars Sales by Application (2019-2024) & (K Units)
Table 39. Global Biologics and Biosimilars Sales by Application (2025-2030) & (K Units)
Table 40. Global Biologics and Biosimilars Sales Market Share by Application (2019-2024)
Table 41. Global Biologics and Biosimilars Sales Market Share by Application (2025-2030)
Table 42. Global Biologics and Biosimilars Revenue by Application 2019 VS 2023 VS 2030 (K Units)
Table 43. Global Biologics and Biosimilars Revenue by Application (2019-2024) & (K Units)
Table 44. Global Biologics and Biosimilars Revenue by Application (2025-2030) & (K Units)
Table 45. Global Biologics and Biosimilars Revenue Market Share by Application (2019-2024)
Table 46. Global Biologics and Biosimilars Revenue Market Share by Application (2025-2030)
Table 47. Global Biologics and Biosimilars Sales by Region: 2019 VS 2023 VS 2030 (K Units)
Table 48. Global Biologics and Biosimilars Sales by Region (2019-2024) & (K Units)
Table 49. Global Biologics and Biosimilars Sales Market Share by Region (2019-2024)
Table 50. Global Biologics and Biosimilars Sales Forecasted by Region (2025-2030) & (K Units)
Table 51. Global Biologics and Biosimilars Sales Forecasted Market Share by Region (2025-2030)
Table 52. North America Biologics and Biosimilars Sales Growth Rate by Country: 2019 VS 2023 VS 2030 (K Units)
Table 53. North America Biologics and Biosimilars Sales by Country (2019-2024) & (K Units)
Table 54. North America Biologics and Biosimilars Sales by Country (2025-2030) & (K Units)
Table 55. Europe Biologics and Biosimilars Sales Growth Rate by Country: 2019 VS 2023 VS 2030 (K Units)
Table 56. Europe Biologics and Biosimilars Sales by Country (2019-2024) & (K Units)
Table 57. Europe Biologics and Biosimilars Sales by Country (2025-2030) & (K Units)
Table 58. Asia Pacific Biologics and Biosimilars Sales Growth Rate by Country: 2019 VS 2023 VS 2030 (K Units)
Table 59. Asia Pacific Biologics and Biosimilars Sales by Country (2019-2024) & (K Units)
Table 60. Asia Pacific Biologics and Biosimilars Sales by Country (2025-2030) & (K Units)
Table 61. LAMEA Biologics and Biosimilars Sales Growth Rate by Country: 2019 VS 2023 VS 2030 (K Units)
Table 62. LAMEA Biologics and Biosimilars Sales by Country (2019-2024) & (K Units)
Table 63. LAMEA Biologics and Biosimilars Sales by Country (2025-2030) & (K Units)
Table 64. Global Biologics and Biosimilars Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 65. Global Biologics and Biosimilars Revenue by Region (2019-2024) & (US$ Million)
Table 66. Global Biologics and Biosimilars Revenue by Region (2025-2030) & (US$ Million)
Table 67. Global Biologics and Biosimilars Revenue Market Share by Region (2019-2024)
Table 68. Global Biologics and Biosimilars Revenue Market Share by Region (2025-2030)
Table 69. Roche Company Information
Table 70. Roche Business Overview
Table 71. Roche Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 72. Roche Biologics and Biosimilars Product Portfolio
Table 73. Roche Recent Development
Table 74. Amgen Company Information
Table 75. Amgen Business Overview
Table 76. Amgen Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 77. Amgen Biologics and Biosimilars Product Portfolio
Table 78. Amgen Recent Development
Table 79. AbbVie Company Information
Table 80. AbbVie Business Overview
Table 81. AbbVie Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 82. AbbVie Biologics and Biosimilars Product Portfolio
Table 83. AbbVie Recent Development
Table 84. Sanofi-Aventis Company Information
Table 85. Sanofi-Aventis Business Overview
Table 86. Sanofi-Aventis Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 87. Sanofi-Aventis Biologics and Biosimilars Product Portfolio
Table 88. Sanofi-Aventis Recent Development
Table 89. Johnson & Johnson Company Information
Table 90. Johnson & Johnson Business Overview
Table 91. Johnson & Johnson Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 92. Johnson & Johnson Biologics and Biosimilars Product Portfolio
Table 93. Johnson & Johnson Recent Development
Table 94. Pfizer Company Information
Table 95. Pfizer Business Overview
Table 96. Pfizer Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 97. Pfizer Biologics and Biosimilars Product Portfolio
Table 98. Pfizer Recent Development
Table 99. Novo Nordisk Company Information
Table 100. Novo Nordisk Business Overview
Table 101. Novo Nordisk Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 102. Novo Nordisk Biologics and Biosimilars Product Portfolio
Table 103. Novo Nordisk Recent Development
Table 104. Eli Lilly Company Information
Table 105. Eli Lilly Business Overview
Table 106. Eli Lilly Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 107. Eli Lilly Biologics and Biosimilars Product Portfolio
Table 108. Eli Lilly Recent Development
Table 109. Novartis Company Information
Table 110. Novartis Business Overview
Table 111. Novartis Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 112. Novartis Biologics and Biosimilars Product Portfolio
Table 113. Novartis Recent Development
Table 114. Merck Company Information
Table 115. Merck Business Overview
Table 116. Merck Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 117. Merck Biologics and Biosimilars Product Portfolio
Table 118. Merck Recent Development
Table 119. 3sbio Company Information
Table 120. 3sbio Business Overview
Table 121. 3sbio Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 122. 3sbio Biologics and Biosimilars Product Portfolio
Table 123. 3sbio Recent Development
Table 124. Changchun High Tech Company Information
Table 125. Changchun High Tech Business Overview
Table 126. Changchun High Tech Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 127. Changchun High Tech Biologics and Biosimilars Product Portfolio
Table 128. Changchun High Tech Recent Development
Table 129. CP Guojian Company Information
Table 130. CP Guojian Business Overview
Table 131. CP Guojian Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 132. CP Guojian Biologics and Biosimilars Product Portfolio
Table 133. CP Guojian Recent Development
Table 134. Biotech Company Information
Table 135. Biotech Business Overview
Table 136. Biotech Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 137. Biotech Biologics and Biosimilars Product Portfolio
Table 138. Biotech Recent Development
Table 139. Gelgen Company Information
Table 140. Gelgen Business Overview
Table 141. Gelgen Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 142. Gelgen Biologics and Biosimilars Product Portfolio
Table 143. Gelgen Recent Development
Table 144. Innovent Company Information
Table 145. Innovent Business Overview
Table 146. Innovent Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 147. Innovent Biologics and Biosimilars Product Portfolio
Table 148. Innovent Recent Development
Table 149. Dong Bao Company Information
Table 150. Dong Bao Business Overview
Table 151. Dong Bao Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 152. Dong Bao Biologics and Biosimilars Product Portfolio
Table 153. Dong Bao Recent Development
Table 154. Ganlee Company Information
Table 155. Ganlee Business Overview
Table 156. Ganlee Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 157. Ganlee Biologics and Biosimilars Product Portfolio
Table 158. Ganlee Recent Development
Table 159. United Laboratories Company Information
Table 160. United Laboratories Business Overview
Table 161. United Laboratories Biologics and Biosimilars Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 162. United Laboratories Biologics and Biosimilars Product Portfolio
Table 163. United Laboratories Recent Development
Table 164. Key Raw Materials
Table 165. Raw Materials Key Suppliers
Table 166. Biologics and Biosimilars Distributors List
Table 167. Biologics and Biosimilars Customers List
Table 168. Research Programs/Design for This Report
Table 169. Authors List of This Report
Table 170. Secondary Sources
Table 171. Primary Sources
LIST OF FIGURES
Figure 1. Biologics and Biosimilars Product Picture
Figure 2. Global Biologics and Biosimilars Market Size (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Biologics and Biosimilars Market Size (2019-2030) & (US$ Million)
Figure 4. Global Biologics and Biosimilars Sales (2019-2030) & (K Units)
Figure 5. Global Biologics and Biosimilars Average Price (USD/Unit) & (2019-2030)
Figure 6. Global Top 5 and 10 Biologics and Biosimilars Players Market Share by Revenue in 2023
Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. Monoclonal Antibodies Picture
Figure 9. Interferon Picture
Figure 10. Erythropoietin Picture
Figure 11. Insulin Picture
Figure 12. Vaccines Picture
Figure 13. Others Picture
Figure 14. Global Biologics and Biosimilars Sales by Type (2019 VS 2023 VS 2030) & (K Units)
Figure 15. Global Biologics and Biosimilars Sales Market Share 2019 VS 2023 VS 2030
Figure 16. Global Biologics and Biosimilars Sales Market Share by Type (2019-2030)
Figure 17. Global Biologics and Biosimilars Revenue by Type (2019 VS 2023 VS 2030) & (K Units)
Figure 18. Global Biologics and Biosimilars Revenue Market Share 2019 VS 2023 VS 2030
Figure 19. Global Biologics and Biosimilars Revenue Market Share by Type (2019-2030)
Figure 20. Tumor Picture
Figure 21. Diabetes Picture
Figure 22. Cardiovascular Picture
Figure 23. Hemophilia Picture
Figure 24. Others Picture
Figure 25. Global Biologics and Biosimilars Sales by Application (2019 VS 2023 VS 2030) & (K Units)
Figure 26. Global Biologics and Biosimilars Sales Market Share 2019 VS 2023 VS 2030
Figure 27. Global Biologics and Biosimilars Sales Market Share by Application (2019-2030)
Figure 28. Global Biologics and Biosimilars Revenue by Application (2019 VS 2023 VS 2030) & (K Units)
Figure 29. Global Biologics and Biosimilars Revenue Market Share 2019 VS 2023 VS 2030
Figure 30. Global Biologics and Biosimilars Revenue Market Share by Application (2019-2030)
Figure 31. North America Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 32. North America Biologics and Biosimilars Sales Market Share by Country (2019-2030)
Figure 33. U.S. Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 34. Canada Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 35. Europe Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 36. Europe Biologics and Biosimilars Sales Market Share by Country (2019-2030)
Figure 37. Germany Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 38. France Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 39. U.K. Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 40. Italy Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 41. Netherlands Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 42. Asia Pacific Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 43. Asia Pacific Biologics and Biosimilars Sales Market Share by Country (2019-2030)
Figure 44. China Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 45. Japan Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 46. South Korea Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 47. Southeast Asia Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 48. India Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 49. Australia Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 50. LAMEA Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 51. LAMEA Biologics and Biosimilars Sales Market Share by Country (2019-2030)
Figure 52. Mexico Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 53. Brazil Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 54. Turkey Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 55. GCC Countries Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 56. Global Biologics and Biosimilars Revenue (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
Figure 57. Global Biologics and Biosimilars Revenue Market Share by Region in Percentage: 2023 Versus 2030
Figure 58. North America Biologics and Biosimilars Revenue (2019-2030) & (US$ Million)
Figure 59. North America Biologics and Biosimilars Revenue Share by Country: 2019 VS 2023 VS 2030
Figure 60. Europe Biologics and Biosimilars Revenue (2019-2030) & (US$ Million)
Figure 61. Europe Biologics and Biosimilars Revenue Share by Country: 2019 VS 2023 VS 2030
Figure 62. Asia-Pacific Biologics and Biosimilars Revenue (2019-2030) & (US$ Million)
Figure 63. Asia-Pacific Biologics and Biosimilars Revenue Share by Country: 2019 VS 2023 VS 2030
Figure 64. LAMEA Biologics and Biosimilars Revenue (2019-2030) & (US$ Million)
Figure 65. LAMEA Biologics and Biosimilars Revenue Share by Country: 2019 VS 2023 VS 2030
Figure 66. Biologics and Biosimilars Value Chain
Figure 67. Manufacturing Cost Structure
Figure 68. Biologics and Biosimilars Production Mode & Process
Figure 69. Direct Comparison with Distribution Share
Figure 70. Distributors Profiles
Figure 71. Years Considered
Figure 72. Research Process
Figure 73. Key Executives Interviewed
Figure 1. Biologics and Biosimilars Product Picture
Figure 2. Global Biologics and Biosimilars Market Size (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Biologics and Biosimilars Market Size (2019-2030) & (US$ Million)
Figure 4. Global Biologics and Biosimilars Sales (2019-2030) & (K Units)
Figure 5. Global Biologics and Biosimilars Average Price (USD/Unit) & (2019-2030)
Figure 6. Global Top 5 and 10 Biologics and Biosimilars Players Market Share by Revenue in 2023
Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. Monoclonal Antibodies Picture
Figure 9. Interferon Picture
Figure 10. Erythropoietin Picture
Figure 11. Insulin Picture
Figure 12. Vaccines Picture
Figure 13. Others Picture
Figure 14. Global Biologics and Biosimilars Sales by Type (2019 VS 2023 VS 2030) & (K Units)
Figure 15. Global Biologics and Biosimilars Sales Market Share 2019 VS 2023 VS 2030
Figure 16. Global Biologics and Biosimilars Sales Market Share by Type (2019-2030)
Figure 17. Global Biologics and Biosimilars Revenue by Type (2019 VS 2023 VS 2030) & (K Units)
Figure 18. Global Biologics and Biosimilars Revenue Market Share 2019 VS 2023 VS 2030
Figure 19. Global Biologics and Biosimilars Revenue Market Share by Type (2019-2030)
Figure 20. Tumor Picture
Figure 21. Diabetes Picture
Figure 22. Cardiovascular Picture
Figure 23. Hemophilia Picture
Figure 24. Others Picture
Figure 25. Global Biologics and Biosimilars Sales by Application (2019 VS 2023 VS 2030) & (K Units)
Figure 26. Global Biologics and Biosimilars Sales Market Share 2019 VS 2023 VS 2030
Figure 27. Global Biologics and Biosimilars Sales Market Share by Application (2019-2030)
Figure 28. Global Biologics and Biosimilars Revenue by Application (2019 VS 2023 VS 2030) & (K Units)
Figure 29. Global Biologics and Biosimilars Revenue Market Share 2019 VS 2023 VS 2030
Figure 30. Global Biologics and Biosimilars Revenue Market Share by Application (2019-2030)
Figure 31. North America Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 32. North America Biologics and Biosimilars Sales Market Share by Country (2019-2030)
Figure 33. U.S. Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 34. Canada Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 35. Europe Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 36. Europe Biologics and Biosimilars Sales Market Share by Country (2019-2030)
Figure 37. Germany Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 38. France Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 39. U.K. Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 40. Italy Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 41. Netherlands Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 42. Asia Pacific Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 43. Asia Pacific Biologics and Biosimilars Sales Market Share by Country (2019-2030)
Figure 44. China Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 45. Japan Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 46. South Korea Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 47. Southeast Asia Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 48. India Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 49. Australia Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 50. LAMEA Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 51. LAMEA Biologics and Biosimilars Sales Market Share by Country (2019-2030)
Figure 52. Mexico Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 53. Brazil Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 54. Turkey Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 55. GCC Countries Biologics and Biosimilars Sales and Growth Rate (2019-2030) & (K Units)
Figure 56. Global Biologics and Biosimilars Revenue (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
Figure 57. Global Biologics and Biosimilars Revenue Market Share by Region in Percentage: 2023 Versus 2030
Figure 58. North America Biologics and Biosimilars Revenue (2019-2030) & (US$ Million)
Figure 59. North America Biologics and Biosimilars Revenue Share by Country: 2019 VS 2023 VS 2030
Figure 60. Europe Biologics and Biosimilars Revenue (2019-2030) & (US$ Million)
Figure 61. Europe Biologics and Biosimilars Revenue Share by Country: 2019 VS 2023 VS 2030
Figure 62. Asia-Pacific Biologics and Biosimilars Revenue (2019-2030) & (US$ Million)
Figure 63. Asia-Pacific Biologics and Biosimilars Revenue Share by Country: 2019 VS 2023 VS 2030
Figure 64. LAMEA Biologics and Biosimilars Revenue (2019-2030) & (US$ Million)
Figure 65. LAMEA Biologics and Biosimilars Revenue Share by Country: 2019 VS 2023 VS 2030
Figure 66. Biologics and Biosimilars Value Chain
Figure 67. Manufacturing Cost Structure
Figure 68. Biologics and Biosimilars Production Mode & Process
Figure 69. Direct Comparison with Distribution Share
Figure 70. Distributors Profiles
Figure 71. Years Considered
Figure 72. Research Process
Figure 73. Key Executives Interviewed
